X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS NOVARTIS DR. DATSONS LABS/
NOVARTIS
 
P/E (TTM) x -10.9 348.2 - View Chart
P/BV x 0.2 38.6 0.4% View Chart
Dividend Yield % 0.0 1.2 -  

Financials

 DR. DATSONS LABS   NOVARTIS
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
NOVARTIS
Mar-18
DR. DATSONS LABS/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs126758 16.6%   
Low Rs31579 5.3%   
Sales per share (Unadj.) Rs133.0228.4 58.2%  
Earnings per share (Unadj.) Rs0.231.7 0.5%  
Cash flow per share (Unadj.) Rs6.632.8 20.2%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs128.8297.1 43.3%  
Shares outstanding (eoy) m31.6624.69 128.2%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.62.9 20.1%   
Avg P/E ratio x516.121.1 2,450.3%  
P/CF ratio (eoy) x11.820.4 58.0%  
Price / Book Value ratio x0.62.2 27.0%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m2,47716,505 15.0%   
No. of employees `000NA0.7 0.0%   
Total wages/salary Rs m561,445 3.9%   
Avg. sales/employee Rs ThNM8,441.3-  
Avg. wages/employee Rs ThNM2,163.6-  
Avg. net profit/employee Rs ThNM1,173.1-  
INCOME DATA
Net Sales Rs m4,2115,639 74.7%  
Other income Rs m791,718 4.6%   
Total revenues Rs m4,2897,357 58.3%   
Gross profit Rs m569-63 -909.8%  
Depreciation Rs m20425 807.9%   
Interest Rs m43055 777.9%   
Profit before tax Rs m131,575 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6792 0.8%   
Profit after tax Rs m5784 0.6%  
Gross profit margin %13.5-1.1 -1,218.4%  
Effective tax rate %48.050.3 95.6%   
Net profit margin %0.113.9 0.8%  
BALANCE SHEET DATA
Current assets Rs m6,8529,522 72.0%   
Current liabilities Rs m6,7113,296 203.6%   
Net working cap to sales %3.3110.4 3.0%  
Current ratio x1.02.9 35.3%  
Inventory Days Days16137 439.3%  
Debtors Days Days31828 1,120.5%  
Net fixed assets Rs m3,67346 7,984.8%   
Share capital Rs m317123 256.6%   
"Free" reserves Rs m3,7617,213 52.1%   
Net worth Rs m4,0787,336 55.6%   
Long term debt Rs m1,6710-   
Total assets Rs m12,63311,105 113.8%  
Interest coverage x1.029.5 3.5%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.30.5 65.6%   
Return on assets %3.47.6 45.6%  
Return on equity %0.110.7 1.1%  
Return on capital %7.722.2 34.5%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96461 1,590.8%   
Fx outflow Rs m6073,630 16.7%   
Net fx Rs m357-3,570 -10.0%   
CASH FLOW
From Operations Rs m1,3451,610 83.5%  
From Investments Rs m-2,256687 -328.3%  
From Financial Activity Rs m-1,200-2,677 44.8%  
Net Cashflow Rs m-2,111-380 556.0%  

Share Holding

Indian Promoters % 4.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 2.0 -  
FIIs % 1.4 1.6 84.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 21.5 437.7%  
Shareholders   20,807 41,647 50.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  ABBOTT INDIA  FRESENIUS KABI ONCO.  

Compare DR. DATSONS LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY18); Net Profit Up 809.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, NOVARTIS has posted a net profit of Rs 265 m (up 809.6% YoY). Sales on the other hand came in at Rs 1 bn (down 13.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS